Skip to main content Accessibility help
×
Home

Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

  • Richard Weisler, Joel Young, Greg Mattingly, Joseph Gao, Liza Squires, Lenard Adler and 304 Study Group...

Abstract

Objective: To evaluate the long-term safety and effectiveness of lisdexamfetamine dimesylate (LDX) in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD).

Methods: Following a 4-week, placebo-controlled, double-blind trial, 349 adults with ADHD were enrolled into an open-label, single-arm study for up to 12 months. Treatment was initiated at 30 mg/day and titrated up to 70 mg/day at subsequent visits to achieve optimal effectiveness and tolerability. Safety assessments included adverse events inquiries, vital signs, and electrocardiograms while the primary effectiveness assessment was the ADHD Rating Scale (ADHD-RS) total score.

Results: A total of 191 (54.7%) subjects completed the study. The most common treatment-emergent adverse events (TEAEs) were upper respiratory tract infection (21.8%), insomnia (19.5%), headache (17.2%), dry mouth (16.6%), decreased appetite (14.3%), and irritability (11.2%). Most TEAEs were mild to moderate in severity. At endpoint, small but statistically significant increases in pulse and blood pressure were noted. Significant improvements in mean ADHD-RS total scores were observed at week 1 and sustained throughout the study (P<.0001 at all postbaseline visits). At endpoint, the mean improvement from baseline ADHD-RS total score was 24.8 (P<.0001).

Conclusions: LDX demonstrated a safety profile consistent with long-acting stimulant use and provided continued effectiveness in adults with ADHD for up to 12 months.

Copyright

Corresponding author

700 Spring Forest, Suite 125, Raleigh, NC 27609; Tel: 919-872-5900, Fax: 919-878-0942; e-mail: RWeisler@aol.com.

References

Hide All
1.Polanczyk, G, de Lima, MS, Horta, BL, Biederman, J, Rohde, LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942948.
2.Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. Washington, DC: American Psychiatric Association; 2000.
3.Barkley, RA, Fischer, M, Edelbrock, CS, Smallish, L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29:546557.
4.Barkley, RA, Fischer, M, Smallish, L, Fletcher, K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111:279289.
5.Biederman, J, Mick, E, Faraone, SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157:816818.
6.Kessler, RC, Adler, L, Barkley, R, et al.The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716723.
7.Biederman, J, Faraone, SV, Spencer, TJ, Mick, E, Monuteaux, MC, Aleardi, M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67:524540.
8.Biederman, J, Mick, E, Fried, R, Aleardi, M, Potter, A, Herzig, K. A simulated workplace experience for nonmedicated adults with and without ADHD. Psychiatr Serv. 2005;56:16171620.
9.Greenhill, LL, Pliszka, S, Dulcan, MK, et al.Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 suppl):26S49S.
10.Wilens, TE, Dodson, W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry. 2004;65:13011313.
11.Faraone, SV, Spencer, TJ, Montano, CB, Biederman, J. Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;164:12211226.
12.Spencer, T, Wilens, T, Biederman, J, Faraone, SV, Ablon, JS, Lapey, K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434443.
13.Spencer, T, Biederman, J, Wilens, T, et al.Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58:775782.
14.Weisler, RH, Biederman, J, Spencer, TJ, et al, on behalf of the SLI381.303 Study Group. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11:625639.
15.Fallu, A, Richard, C, Prinzo, R, Binder, C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin. 2006;22:25572566.
16.Biederman, J, Mick, E, Surman, C, et al.A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59:829835.
17.Weisler, RH, Biederman, J, Spencer, TJ, Wilens, TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 suppl 20):3543.
18.Wilens, TE, Hammerness, PG, Biederman, J, et al.Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005;66:253259.
19.Nutt, DJ, Fone, K, Asherson, P, et al.Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21:1041.
20.Adler, LA, Reingold, LS, Morrill, MS, Wilens, TE. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8:409415.
21.Philipsen, A, Hornyak, M, Riemann, D. Sleep and sleep disorders in adults with attention deficit/hyperactivity disorder. Sleep Med Rev. 2006;10:399405.
22.Mick, E, Biederman, J, Jetton, J, Faraone, SV. Sleep disturbances associated with attention deficit hyperactivity disorder: the impact of psychiatric comorbidity and pharmacotherapy. J Child Adolesc Psychopharmacol. 2000;10:223231.
23.Owens, JA. The ADHD and sleep conundrum: a review. J Dev Behav Pediatr. 2005;26:312322.
24.Carlson, GA, Kelly, KL. Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol. 2003;13:137142.
25.Mattingly, GW. ADHD, Psychostimulants and sleep disorders: is there a link? The Year in ADHD: 2008. 2009;1:3237.
26.Pennick, M. Absorption of lisdexamfetamine dimesylate and hydrolysis to form the active moiety, d-amphetamine. Poster presented at: New Clinical Drug Evaluation Unit 49th Annual Meeting; June 29-July 2, 2009; Hollywood, FL.
27.Pennick, M. Hydrolytic conversion of lisdexamfetamine dimesylate to the active moiety, d-amphetamine. Poster presented at: Society of Biological Psychiatry's 64th Annual Scientific Convention and Meeting; May 14-16, 2009; Vancouver, British Columbia, Canada.
28.Shojaei, A, Ermer, JC, Krishnan, S. Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects. Poster presented at: 160th Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, CA. Poster NR 740.
29.Krishnan, S, Zhang, Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol. 2008;48:293302.
30.Ermer, J, Homolka, R, Martin, P, Buckwalter, M, Purkayastha, J, Roesch, BG. Linear dose proportionality, low inter- and intrasubject variability, and safety of lisdexamfetamine dimesylate in an open-label single-dose pharmacokinetic study in healthy adult volunteers. Poster presented at: 37th Annual Meeting of the American College of Clinical Pharmacy Annual Meeting; October 19-22, 2008; Louisville, KY. Poster 201.
31.Biederman, J, Krishnan, S, Zhang, Y, McGough, JJ, Findling, RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forceddose, parallel-group study. Clin Ther. 2007;29:450463.
32.Biederman, J, Boellner, SW, Childress, A, Lopez, FA, Krishnan, S, Zhang, Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62:970976.
33.Wigal, SB, Kollins, SH, Childress, AC, Squires, L, for the 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.
34.Adler, LA, Goodman, DW, Kollins, SH, et al, on behalf of the 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69:13641373.
35.Findling, RL, Childress, AC, Krishnan, S, McGough, JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 2008;13:614620.
36.Adler, L, Cohen, J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:187201.
37. ADHD-RS Initial Evaluation. Available at: http://www.askdrjones.com/wp-content/uploads/patientforms/ADHD%20Screening-Initial%20Eval.pdf. Accessed August 12, 2009.
38.Buysse, DJ, Reynolds, CF III, Monk, TH, Berman, SR, Kupfer, DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193213.
39.Biederman, J, Spencer, TJ, Wilens, TE, Weisler, RH, Read, SC, Tulloch, SJ, on behalf of the SLI 381.304 Study Group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):1625.
40.Adderall, XR [package insert]. Wayne, PA: Shire US Inc; 2009.
41. Concerta [package insert]. Titusville, NJ: McNeil Pediatrics; 2009.
42.Focalin, XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
43.Adler, LA, Spencer, TJ, Williams, DW, Moore, RJ, Michelson, D. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008;12:248253.
44. Vyvanse [package insert]. Wayne, PA: Shire US Inc; 2009.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed